7 news items
Biotech Sector Working to Combat Rising Cases of Colorectal Cancer in Young Adults
BMY
CCCC
ONCY
28 May 24
. (NASDAQ:TCRX), which is currently in Phase I for anal cancer. TSC-200-A0201 targets HPV16 on HLA type A*02:01
Biotech Sector Working to Combat Rising Cases of Colorectal Cancer in Young Adults
BMY
CCCC
ONCY
28 May 24
. (NASDAQ:TCRX), which is currently in Phase I for anal cancer. TSC-200-A0201 targets HPV16 on HLA type A*02:01
Key Takeaways From C4 Therapeutics Analyst Ratings
CCCC
9 May 24
In the assessment of 12-month price targets, analysts unveil insights for C4 Therapeutics, presenting an average target
Wells Fargo Maintains Equal-Weight on C4 Therapeutics, Raises Price Target to $8
CCCC
9 May 24
Wells Fargo analyst Derek Archila maintains C4 Therapeutics (NASDAQ:CCCC) with a Equal-Weight and raises the price target from $7 to $8.
Stifel Maintains Buy on C4 Therapeutics, Raises Price Target to $14
CCCC
9 May 24
Stifel analyst Bradley Canino maintains C4 Therapeutics (NASDAQ:CCCC) with a Buy and raises the price target from $13 to $14.
bc7bv8dzhj08anxyunvzlbqkrmgewtlwfepgsx5zbat3r 9b8hafum87eq
CCCC
8 Apr 24
biopharmaceutical company dedicated to advancing targeted protein degradation science, presented a poster today at the American Association for Cancer Research
sbmw74jsg4 mlovdz8ayb755g3qz1n35ks5obh9zyf8tbh75
CCCC
5 Mar 24
biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced the acceptance of two preclinical poster presentations
- Prev
- 1
- Next